Trans-membrane receptor tyrosine kinases play an important role in the modulation of growth factor signalling ... are competitive inhibitors at the tyrosine kinase ATP binding site.

EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. The discovery of EGFR mutations has ...

Among the recent advances in the molecular targeted therapy of cancer, the applications focused on epidermal growth factor receptor ... antibodies and tyrosine kinase inhibitors (TKI), it is ...

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation, Cochrane ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

The epidermal growth factor receptor (EGFR) is a target found in high concentrations in several solid tumors including lung, breast, colorectal, and brain. Tyrosine kinase inhibitors, such as ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.